Less than 20% of patients that could benefit from TAVR are receiving it

 The introduction of transcatheter aortic valve replacement procedures (TAVR) seems to have increased the number of elderly patients hospitalized with severe aortic stenosis, as well as the number of interventions. However, less than one fifth of patients over 85 are intervened, according to a Canadian registry.

 

Given the significant difference in mortality with TAVR, observed even in elderly patients, it is vital to call the attention of clinical cardiologists.

 

Using data of 37,970 patients hospitalized between 2004 and 2013 with primary or secondary aortic stenosis, repeat interventions and mortality rates were followed up at one year.

 

Hospitalization rates increased from 36 to 39% during this period (p<0.001). Similarly, intervention rates (TAVR or surgery) within 12 months after initial hospitalization, increased from 39% in 2004 to 44% in 2013 (p<0.001), with the largest increase in patients over 85 (5% to 18%; p<0.001).

 

A huge limitation to this study, is that there are no registries of echocardiographic data or symptoms, which is why we are not able to tell the number of patients that really needed a valve intervention and would not get it, but we are under the impression that it is lower than it should be.

 

Lastly, after the first hospitalization, mortality at 30 days was 12%, and at one year, 26%. These rates remained stable for the whole study period.

 

For those undergoing a valve intervention (TAVR or surgery), mortality did improve in time.

 

Original Title: Trends in the hospitalization rates and outcomes of patients with aortic stenosis from 2004 to 2013.

Presenter:  Czarnecki A.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....